Health Care · Electromedical & Electrotherapeutic Apparatus

CBLL Ceribell, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1861107108 filings
Russell 2000

CBLL at a glance

Ceribell, Inc. (CBLL, SEC CIK 1861107) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Ceribell, Inc. (CBLL) reported revenue of $89.1 million (up 36.1% from FY2024) and a net loss of $53.4 million. Diluted EPS was -$1.46.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Ceribell, Inc. (CBLL) shares worth $225.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Parvizi Josef on November 16, 2026 of 25,000 shares at $26.02 per share.
  • In the last 90 days, CBLL insiders reported 0 open-market purchases ($0) and 14 open-market sales ($3.6M) on Form 4, a net sale of $3.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$89.1M
+36.1% vs prior year
Insiders · 90 days
0 buys · 14 sells
Net −$3.6M
13F holders
24 funds
$225.3M · −2 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $29.3M, up 30% YoY from $22.6M, driven by product revenue of $22.2M
  • Product revenue, best performer, $22.2M, up 31% YoY versus subscription revenue $7.1M, up 28%
  • Gross profit $26.3M versus $19.9M YoY, gross-margin percentages not provided in filing tables
  • Operating loss $20.5M versus $14.6M YoY, net loss $21.4M versus $13.5M
  • Cash, equivalents and marketable securities $117.5M; nine-month operating cash outflow $45.2M versus $30.0M YoY

Risk Factors

  • New QMSR compliance risk triggered by FDA’s February 2, 2026 effective rule, potentially increasing costs and regulatory requirements
  • Reimbursement risk changed materially: Clarity’s electrographic-status-epilepticus NTAP expired September 30, 2026
  • New-product risk from Delirium Monitor System NTAP, effective October 1, 2026, being temporary and not assuring adoption
  • Supply-chain risk from China and Vietnam manufacturing, with tariffs potentially raising costs and disrupting availability
  • Liquidity risk: $60.4 million net loss and $280.7 million accumulated deficit for the nine months ended September 30, 2026

AI summary of the CBLL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended September 30, 2026
  • Press release dated November 3, 2026 contains financial results and investor-relevant operating details

Item EX-99.1: Item EX-99.1

  • Q3 revenue $29.3M, up 30% year over year, with product revenue $22.2M and subscription revenue $7.1M
  • 747 active accounts and 35 net new customers, supporting durable utilization-led growth
Filed Aug 10, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $28.1M, up 33%; product revenue $21.2M and subscription revenue $6.9M signal broad adoption
  • Gross margin reached 92% versus 88%, supported by Vietnam manufacturing and one-time tariff refunds

Item 2.02: Results of Operations and Financial Condition

  • Ceribell announced financial results for the quarter ended June 30, 2026
  • Full results and management commentary are contained in Exhibit 99.1, dated August 10, 2026
Filed Jul 30, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from seven to nine directors, creating two new seats
  • Burke and Taylor shifted from Class I to Classes II and III, respectively, balancing three directors per class

AI summaries of CBLL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CBLL

Don't miss the next CBLL filing

  • Alerts as it files. A push when CBLL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CBLL, by share count.
  • Ask anything. An AI agent that reads every CBLL filing and answers with sources.

CBLL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Parvizi JosefSellNov 16, 2026$26.02
BURKE WILLIAM WSellNov 12, 2026$27.48
BURKE WILLIAM WSellNov 12, 2026$26.58
BURKE WILLIAM WMNov 12, 2026-
BURKE WILLIAM WMNov 12, 2026$4.70
Taylor Joseph MichaelSellNov 9, 2026$27.22
Woo RaymondMNov 2, 2026-
Woo RaymondMNov 2, 2026$3.65

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$65.4M$89.1M
Gross Profit-$56.8M$78.3M
Operating Income--$39.7M-$58.4M
Net Income--$40.5M-$53.4M
Gross Margin-86.7%87.9%
Op. Margin--60.7%-65.6%
Net Margin--61.8%-60.0%
Balance Sheet
Total Assets$58.9M$225.4M$195.8M
Equity-$191.2M$155.3M
ROE--21.2%-34.4%
Per Share
EPS$-5.56$-3.39$-1.46
Cash Flow
Operating CF--$35.0M-$40.8M
CapEx-$1.3M$767K

Source: XBRL data in Ceribell, Inc. (CBLL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CBLL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CBLL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$225.3M
Q2 202626$276.4M
Q1 202625$244.9M
Q4 202521$245.5M
Q3 202518$126.1M
Q2 202520$190.2M
Q1 202514$135.5M
Q4 202415$187.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 163 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CBLL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 13, 2026--
4Nov 10, 2026--
4Nov 4, 2026--
8-KNov 3, 2026Analysis-
10-QNov 3, 2026Analysis
4Oct 2, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 17, 2026--
4Aug 14, 2026--
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-

Related Health Care companies

All Health Care →

CBLL SEC filings: frequently asked questions

Are CBLL insiders buying or selling?

In the last 90 days, Ceribell, Inc. (CBLL) officers, directors and 10% owners reported no open-market purchases and 14 open-market sales worth $3.6 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CBLL stock?

As of September 30, 2026, the largest Ceribell, Inc. (CBLL) holders among the 13F filers tracked by SignalX were BlackRock ($51.5 million), Vanguard Capital Management LLC ($33.0 million), Franklin Resources ($25.3 million), State Street Corp ($15.3 million), JPMorgan Chase & Co ($14.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CBLL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Ceribell, Inc. (CBLL) reported revenue of $89.1 million (up 36.1% from FY2024) and a net loss of $53.4 million. Diluted EPS was -$1.46. The figures come from the XBRL data in the 10-K.

What did CBLL report in its latest 8-K?

Ceribell, Inc. (CBLL) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.

What are the latest CBLL SEC filings?

Ceribell, Inc. (CBLL) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 17, 2026.

What is CBLL's SEC CIK number?

Ceribell, Inc. (CBLL)'s SEC Central Index Key (CIK) is 1861107. EDGAR lists every CBLL filing under that number.

Ask anything about CBLL

The research agent reads CBLL's filings, financials, insider trades and 13F holders, then answers with sources.